- /
- Supported exchanges
- / US
- / PCVX.NASDAQ
Vaxcyte Inc (PCVX NASDAQ) stock market data APIs
Vaxcyte Inc Financial Data Overview
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vaxcyte Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Vaxcyte Inc data using free add-ons & libraries
Get Vaxcyte Inc Fundamental Data
Vaxcyte Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -799 798 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -1.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vaxcyte Inc News
New
Vaxcyte's Chief Technical Ops Officer Sells Shares
Key Points The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings. These 10 stocks could mint the next wave of millionaires › Chief Technical Ops Officer Sells 9,743 Shares ...
Vaxcyte's Chief Technical Ops Officer Sells Shares
Key Points The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings.These 10 stocks could mint the next wave of millionaires › Chief Technical Ops Officer Sells 9,743 Shares F...
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
Vaxcyte stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note. Vaxcyte is advancing to phase 3 tr...
What Makes Vaxcyte (PCVX) So Attractive
Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He a...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.